Sodium-glucose co-transporter 2 inhibitors in severe estimated glomerular filtration rate deterioration across cardiovascular-kidney- metabolic conditions: A pooled analysis of randomized trials.

ABSTRACT:

Aims

The efficacy of sodium-glucose co-transporter 2 inhibitors (SGLT2i) among patients with cardiovascular-kidney-metabolic (CKM) conditions who experience severe estimated glomerular filtration rate (eGFR) deterioration during follow-up is not well established. The aim of this study was to assess the risk of cardiovascular outcomes and mortality after eGFR deterioration to <25 ml/min/1.73 m² (and <20 ml/min/1.73 m²), and whether such eGFR deterioration modified the effect of SGLT2i across CKM populations.

Methods and results

Pooled analysis of placebo-controlled trials: EMPEROR-Preserved, EMPEROR-Reduced, EMPA-REG OUTCOME, CANVAS-R, and CREDENCE. Time-updated models with stratification by study were used. The median follow-up to eGFR deterioration was

SUBMITTER: Ferreira JP 

PROVIDER: S-EPMC12765462 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature